Hypoxia-inducible factor-1, A new possible important factor in Neoplasia

Polish Journal of Pathology

Volumn 60, Issue 2, 2009, Pages 61-66

  Rekwirowicz, Hanna ^a   Marszalek, Andrzej ^a,b  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Hypoxia inducible factor 1; Neoplasia

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1;

ANAEROBIC GROWTH; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANAEROBIOSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASMS; TRANSCRIPTION, GENETIC;

EID: 79958091512     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Epstein RJ. Biologia molekularna człowieka. Czelej, Lublin 2005; 465-466.
2. Krszyna K, Stokłosa T. Hypoxia inducible factor-1 (HIF-1): structure, regulation of expression, function and the role in tumor progression. Post Biol Kom 2005; 32: 707-728.
3. Duchnowska R, Szczylik C. Non-hematological role of erythropoietin. Onkol Pol 2003; 3: 109-112.
4. Duffy JP, Eibl G, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2003; 2: 1-10.
5. Gruchlik A, Chodurek E, Domal-Kwiatkowska D, Dzierżewicz Z. VEGF-A-Target of antiangiogenic cancer therapy. Post Biol Kom 2007; 34: 557-580.
6. Ziello JE, Jovin IS, Huang Y. Hypoxia-inducible factor (HIF-1) regulatory, pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 2007; 2: 51-60.
7. André H, Pereira TS. Identification of an alternative mechanism of degradation of the hypoxia-inducible factor-1alpha. J Biol Chem 2008; 43: 29375-84.
8. Mazurkiewicz M, Wasiutyński A. Current opinion in pathogenesis of pheochromocytoma. Pol Merk Lek 2007; 132: 509-513.
9. Zhou J, Hara K, Inoue M. Regulation of hypoxia-inducible factor 1 by glucose availability under hypoxic conditions. Kobe J Med Sci 2008; 6: 283-296.
10. Michiels C. Physiological and pathological responses to hypoxia. Am J Pathol 2004; 164: 1875-1882.
11. Mizia-Malarz A, Sobol G, Woś H. Angiogeneza w przewlekłych schorzeniach zapalnych i nowotworowych. Pol Merk Lek 2008; 141: 185-189.
12. http://www.universityofcalifornia.edu/news/article/7298.
13. Pera J. Ischemic preconditioning. Akt Neurol 2002; 2: 17-25.
14. Skóra J, Biegus J, Pupka A, et al. Molecular basics of angiogenesis. Post Hig Med Dosw 2006; 60: 410-415.
15. Grosicki S, Grosicka A, Hołowiecki J. Clinical importance of angiogenesis and angiogenic factors in oncohematology. Wiad Lek 2007; 1-2: 39-46.
16. Gryczyński M, Piertuszewska W. Angiogenesis as a prognostic factor in patients with laryngeal cancer. Otorynolaryngologia 2002; 1: 13-20
17. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoetins and VEGF. Oncogene 1999; 18: 5356-5362
18. Madej JA: Role of stem cells in tumor structure. Med Weter 2007; 4: 384-388
19. Swidzińska E, Naumnik W, Chyczewska E. Angiogenesis and neoangiogenesis-the role in lung cancer and other tumors. Pneumonol Alergol Pol 2006; 74: 414-420.